SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Daly JM, Karnell LH, Menck HR. National cancer database report on esophageal carcinoma. Cancer. 1996; 78: 1820188.
  • 2
    Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer. 1997; 79: 206213.
  • 3
    Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer. 1997; 79: 220225.
  • 4
    Kitadai Y, Haruma K, Tokutomi T, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res. 1998; 4: 21952200.
  • 5
    Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000; 6: 11611168.
  • 6
    Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br J Cancer. 1997; 76: 689693.
  • 7
    Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishituka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 1995; 14: 7982.
  • 8
    Takebayashi Y, Yamada K, Miyadera K, et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer. 1996; 32: 12271232.
  • 9
    Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996; 88: 11101117.
  • 10
    Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer. 1996; 73: 884888.
  • 11
    Mori K, Hasegawa M, Nishida M, et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tissues. Int J Oncol. 2000; 17: 3338.
  • 12
    Takebayashi Y, Natsugoe S, Baba M, et al. Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer. 1999; 85: 282289.
  • 13
    Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assel O, Nagasue N. The prognostic significance of micro vessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer. 1998; 82: 12251232.
  • 14
    Jin-no K, Tanimizu M, Hyodo I, et al. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients. Cancer. 1998; 82: 12601267.
  • 15
    Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers. Cancer Res. 2000; 60: 36623665.
  • 16
    Sobin LH, Wittekind CH. UICC TNM classification of malignant tumors. 5th ed. New York: John Wiley and Sons, Inc., 1997.
  • 17
    Japanese Committee for Registration of Esophageal Carcinoma Cases. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Chest. 1989; 96: 10051011.
  • 18
    Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissue. Biol Pharm Bull. 1996; 19: 14071411.
  • 19
    Fujida S, Sunaga H, Tsuzuki H, Tanaka N, Saito H. Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma. Clin Cancer Res. 1998; 4: 15831590.
  • 20
    Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res. 1998; 4: 23712376.
  • 21
    Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59: 33743378.
  • 22
    Toi M, Inada K, Hoshino S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res. 1995; 1: 961964.
  • 23
    Amaya H, Tanigawa N, Lu C, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997; 119: 227235.
  • 24
    Fujimoto K, Hosotani R, Wada M, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer. 1998; 34: 14391447.
  • 25
    Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34: 12741281.
  • 26
    Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998; 58: 685690.